Abstract:
Elevated serum cholesterol is an important risk factor associated with atherosclerosis and
coronary heart disease. The aim of the present study was to successfully encapsulate two probiotics
of Limosilactobacillus strain that are LimosiLimosilactobacillusrhamnosus FM9 and
Limosilactobacillus. fermentum Y57 and evaluate their ability to lower serum cholesterol levels in
murine models. These probiotics were encapsulated by spray drying and freeze drying in skim
milk. The freeze dried encapsulated probiotics at 4 ° C namely, L. rhamnosus FM9 and L.
fermentum Y57 exhibited reduction in survival rate by 6.04% and 6.67% while being stored for
three months whereas, at 37 ° C the reduction of survival rate for L. rhamnosus FM9 and L.
fermentum Y57 was 6.3% and 5.2% respectively. In contrast, the spray dried encapsulated
probiotics, L. rhamnosus FM9 and L. fermentum Y57 exhibited reduction in survival rate by 6.12%
and 6.80% over a time period of three months at 4 ° C, whereas, at 37 ° C the reduction of survival
rate for L. rhamnosus FM9 and L. fermentum Y57 was 6.1% and 6.4 % respectively. Furthermore,
a consortium was formulated by using spray dried probiotics. The spray dried probiotics were used
because of their efficiency and ability to be produced in bulk amount as compared to freeze dried
probiotics. The spray dried probiotic consortium was administered in high fat diet model of male
Wistar rats which showed improved lipid profile as compared to statins. The percentages for
probiotic consortium lowering cholesterol and LDL were 11.08%, 34.56% respectively in contrast,
the percentages of statin were 5.1% and 23.6%. Whereas, the HDL was increased by 53.4% for
the group administered with probiotic consortium and for statin the increase was of 12.66%.
Considering all this, the spray dried probiotic consortium administered in murine model showed a
significant decrease in cholesterol levels as compared to the control group administered with
Statin.
